QuidelOrtho Corp. Stock
€24.00
Your prediction
QuidelOrtho Corp. Stock
Pros and Cons of QuidelOrtho Corp. in the next few years
Pros
Cons
Performance of QuidelOrtho Corp. vs. its peers
Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
---|---|---|---|---|---|---|---|
QuidelOrtho Corp. | 6.310% | 8.108% | 10.092% | -39.086% | -42.857% | -72.254% | -88.350% |
Veeva Systems A | 0.740% | 3.545% | 2.265% | 40.006% | 22.195% | 15.301% | 9.697% |
Thermo Fisher Scientific Inc. | 2.290% | 2.057% | 17.368% | -21.496% | -14.539% | -26.397% | 17.384% |
Waters Corp. | -2.200% | 0.441% | 2.372% | -18.442% | -29.612% | -24.013% | 36.033% |
Comments
News

QuidelOrtho (QDEL) Fiscal Q2 EPS Beats
QuidelOrtho (NASDAQ:QDEL), a global provider of diagnostic testing solutions, released its financial results for the quarter ended June 29, 2025, on August 5, 2025. The most notable headline was a

QuidelOrtho to Participate in Upcoming Investor Conferences
QuidelOrtho Corporation (Nasdaq: QDEL) (“QuidelOrtho”), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine

QuidelOrtho Reports First Quarter 2025 Financial Results
QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company” or “QuidelOrtho”), a global provider of innovative in-vitro diagnostic technologies designed for point-of-care settings, clinical labs, and